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of 3D brachytherapy to clinical practice. Trans-vaginal 
ultrasound of cervical cancer offers width, height and 
thickness of cervical tumour and makes HR CTV contouring on 
CT images easier.  
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Purpose/Objective: To present the experience in the daily 
practice of a novel MRI compatible perineal template 
developed in our Department, able to support both: an 
intrauterine probe (SIU) (intracavitary component. IC) and 
titanium needles (TN. Interstitial component) for MRI-Guided 
brachytherapy (BT) applications, in gynecologic malignancies 
There are different manufactured templates for interstitial 
implants as 'Martinez Universal Perineal Interstitial Template' 
(MUPIT) with angled openings or the 'Syed' template. Two 
deficits are inherent to the previously commented currently 
commercially available templates: the IC being difficult to 
reach cervix in depth and the necessity to use CT for the 
dosimetry being both not compatible with MRI.  
Materials and Methods: The developed template, adapts the 
currently existing manufactured MR compatibles intrauterine 
tubes (Nucletron-Elekta) allowing the deliver a large central 
dose, and TN, also compatible with MRI, with the capacity to 
cover the disease in all directions in gynecologic 
malignancies. The template has been developed with the aid 
of Lorca Marín S.A, Murcia, Spain in the manufacturing 
process. In the MRI (General Electric 1,5 tesla) we use a T2 
sequence for delineation of CTV and organ at risk following 
the recommendations of GEC-ESTRO and a 3D radio-
frequency Spoiled Gradient recalled Echo (SPGR) sequence to 
recognized the applicator and TN (Figure). From April 2013 
until November 2014, we have done sixteen implants. 
Fourteen patients were diagnosed of locally advanced cervix 
carcinoma (CC) and 2 vaginal recurrences of papilar serous 
endometrial carcinoma. Median age 66 years (33-77 years). 
Nine were staged as IIB (Figo 2009), 2, IIIB and II IV b. 
Results: In the CC, BT have done after External beam 
radiotherapy (EBRT) over pelvis (median dose 50.4 Gy (48.6- 
53.7 Gy). All patients have received concomitant 
chemotherapy with EBRT. The dose administrated with BT 
have been 6 fractions of 4 Gy in four days in 14 patients, 6 
fractions of 4.25 Gy in one patient because the delay 
between RTE and BT due to comorbidities. The dose has been 
prescribed to IR CTV in all cases following recommendations 
of GEC-ESTRO due to the charactheristics of the interstitial 
implant. Median D90 to IR-CTV calculated with EQD2 in 
patients with locally advance CC (we have excluded the 2 
recurrences in vagina because they are different behavior 
disease) is 80,5 Gy (62-5-84,2) with a median D90 in organ at 
risk (OR): bladder of 77,4 Gy (60,5-90,8Gy) and 69,9 Gy in 
rectum (58,3-83,7 Gy). The median overall survival is 13 
months (2- 19 months) with three patients with local 
persistence after BT. All doses in OR are under limits of GEC 
ESTRO recommendations. 
Conclusions: This new template allows increasing the CTV of 
the BT procedures in locally advanced ginecological tumors in 
4D MRI based BT, improving the possibilities for a more 
adaptative dosimetry with lower doses in OR. 
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Purpose/Objective: Our previous interstitial brachtherapy 
(ISBT) experience was associated higher vaginal toxicities, 
especially for lower vaginal tumors, thus increasing our 
interest in minimizing vaginal wall dose. Previous guidelines 
for vaginal tolerance have been a point dose on the vagina 
wall from intracavitary brachytherapy. Advances in imaging 
and 3-D planning have allowed further investigation into 
volumetric dosimetry. The purpose of this study is to 
investigate whether altered dwell times for vaginal obturator 
needles can reduce the vaginal wall dose without 
compromising the target coverage. 
Materials and Methods: To evaluate dosimetric changes on 
the vaginal wall dose, a vaginal cancer patient with ISBT was 
selected as a patient case. For comparisons, phantom case 
was set up which has parallel needle position as a perfect 
implant with same needle position as patient case. Vaginal 
wall was contoured as 0.5 cm thick volume around the 
vaginal surface of the obturator. Geometric optimization was 
used to create homogenous dose distribution on both 
phantom and patient cases as an initial treatment plan (20 
Gy/4 fractions). To reduce high vaginal wall dose, five 
different plans was created with the modification of dwell 
times on the surface obturator needles relative to a central 
obturator needle. DVH evaluation was done on each plan to 
compare dosimetric parameters. 
Results: The V150% dose was much larger in patient case 
than the phantom case due to the non-parallel needles. The 
modification of dwell times for the vaginal surface needles 
significantly reduced the volume of vagina wall receiving the 
V150% dose from 77.6% to 57.8% and V175% dose from 57.5% 
to 20.2% in patient case. Figure shows dose profiles from the 
vaginal surface of the obturator to the entire target volume 
between the needles (lowest dose area) in the phantom case. 
Modification of using 0% obturator surface needles after 
geometric optimization (plan 3) and no dwell position for 
inner obturator surface needles at the time of geometric 
optimization (plan 4) have lowest vaginal wall dose without 
changing target volume coverage.  
Conclusions: To reduce high dose volume of the vaginal wall, 
we now routinely insert a needle into the central canal of the 
vaginal obturator and modify dwell times at the needles 
along the surface of vaginal obturator to reduce the volume 
of the vaginal wall from exceeding 150% prescription dose.  
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Purpose/Objective: Brachytherapy is the cornerstone of 
radiotherapy treatment in cervical cancer. In the last decade 
an increasing number of publications based on single 
institution large series indicate MR based IGABT as the new 
gold standard of treatment allowing a dramatic decrease of 
morbidity and at the same time an increase in local control 
especially for large tumors. Hereby we describe preliminary 
dosimetric results of MR IGABT at our institution. 
Materials and Methods: Since December 2012, 71 
consecutive patients (median age 50,5; range 31- 88,5) with 
a histologically proven diagnosis of locally advanced cervical 
cancer have been referred to GYN tumor board at our 
Institution.  
FIGO stage distribution was the following: 5 had Ib1, 4 had 
Ib2, 1 had IIA, 28 had IIB with mid proximal parametrial 
invasion, 12 had IIB with distal parametrial invasion, 1 had 
IIIA, 13 had IIIB (11 because pelvic wall invasion), 7 had IVA 
cancers. All cases were Diagnostic routine for all patients 
consisted in thorax and abdomen CT and pelvic MR. PET CT 
was obtained in selected cases. All patients had laparoscopic 
retroperitoneal lymphadenectomy. All patients received 
radio-chemotherapy consisting 3DCRT (45 Gy in 25 fr.) 
concomitant to chemotherapy (weekly cisplatin 40 mg m2) 
followed by 4 fraction of 7 Gy each within two different BT 
insertions. Median overall treatment time was 43 days. 2-3 
days before 1 BT implant all patients had a T2 MR scan to 
define tumor regression during radio-chemotherapy. All BT 
applications were performed under spinal anesthesia with 
TRUS and trans-abdominal US guidance. We used MR 
compatible Tandem Ovoids applicators (Elekta Utercht type) 
or Tandem Ring applicator (Elekta Vienna type) with either 
plastic or titanium needles if needed. At first application all 
patients had an MR with the applicator in place and a i.v. 
contrasted CT. A direct reconstruction approach based on 
applicator library or template was used to reconstruct 
applicators on MR images. Target volumes and OAR were 
contoured on MR according GEC ESTRO reccomendations. In 
all cases we started the planning process with a standard 
point A plan which was subsequently modified in order to 
reach our planning aims that are the following: HRCTV 
D9086Gy EQD2, Bladder D2cc<90 Gy EQD2, Rectum and 
Sigmoid bowel D2cc<70 GyEQD2. In the present study we 
report DVH comparison between Standard and optimized 
plans. 
Results: Preliminary dosimetric results are summarized in fig. 
1. At the present moment we had 2 patients with persistent 
disease after BT. Both cases were large IIIB tumors with 
infiltrative growth pattern and received a D90 dose of 85,21 
and 85,51 Gy EQD2 respectively. No intraoperative or 
perioperative events have been registered so far. 
Conclusions: In our preliminary experience MR based IGABT 
is strikingly superior to standard treatment. 
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Purpose/Objective: Image-Guided brachytherapy (IGBT) is 
related to treatment based on the 3D imaging for the 
planning procedure, not for the evaluation of the precision 
and accuracy of the treatment, which is the goal of the 
Image-Guided radiotherapy (IGRT). The aim of this study was 
assessment of probable intra-fractional organ displacement 
after the 3D imaging of the planning purpose.  
Materials and Methods: Thirty intracavitary bracytherapy 
insertions (with Rotterdam's tandem and ovoid applicators) of 
cervical cancer patients were studied. A CT scanning were 
done for each of the cases, for treatment planning, after the 
applicator insertion. Treatment planning was based on 
getting 80-90 Gy total dose to D90 of the HR-CTV (EQD2) and 
70Gy and 80Gy for rectum and bladder (D2cc), respectively. 
For each of those insertions a second CT scan were 
performed for the patients, just after the finishing of her 
treatment and before the applicators removed from her 
body. The scanning protocols (e.g. the amount of normal 
saline injection to the bladder Foley) were the same as the 
first CT imaging. Organ contouring and applicators 
reconstructions were performed with the same physician and 
physicist. The first 3D treatment planning were copied 
